Get the Stockscreener App
1.0398
0.48%
-0.0002
Jaguar Health Inc stock is traded at $1.0398, with a volume of 109.91K.
It is down -0.48% in the last 24 hours and down -19.14% over the past month.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
109.91K
Relative Volume:
0.37
Market Cap:
$9.60M
Revenue:
$10.72M
Net Income/Loss:
$-39.71M
P/E Ratio:
-0.0669
EPS:
-15.5542
Net Cash Flow:
$-32.21M
1W Performance:
-4.17%
1M Performance:
-19.14%
6M Performance:
-94.58%
1Y Performance:
-94.61%
1-Day Range:
$1.02
$1.05
1-Week Range:
$1.01
$1.1165
52-Week Range:
$0.9501
$30.86
Jaguar Health Inc Stock (JAGX) Company Profile
Name
Jaguar Health Inc
Sector
Industry
Phone
415-371-8300
Address
200 PINE STREET SUITE 400, SAN FRANCISCO, CA
Jaguar Health Inc Stock (JAGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-11-17 | Initiated | Rodman & Renshaw | Buy |
Jaguar Health Inc Stock (JAGX) Latest News
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS) - StockTitan
JAGX (Jaguar Health) Total Inventories : $9.56 Mil (As of Jun. 2024) - GuruFocus.com
Jaguar Health reports promising crofelemer study results - Investing.com
Jaguar Health reports promising crofelemer study results By Investing.com - Investing.com UK
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual MeetingChannel3000.com - Channel3000.com - WISC-TV3
Small-cap biotech Jaguar Health’s stock jumps as it launches treatment for a painful side effect of cancer treatment - MSN
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S. - BioSpace
Small-cap biotech Jaguar Health’s stock jumps 7% as it launches treatment for oral mucositis in cancer patients - MSN
Jaguar Health launches Gelclair for oral mucositis relief By Investing.com - Investing.com South Africa
Jaguar Health’s stock jumps as it launches treatment for oral mucositis - MarketWatch
Jaguar Health launches Gelclair for oral mucositis relief - Investing.com
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - guardonline.com
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum - Corsicana Daily Sun
Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... - Yahoo Finance
Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ... By GuruFocus - Investing.com Canada
Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial - Joplin Globe
Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup - Clinical Trials Arena
Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer - Corsicana Daily Sun
Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patien - AccessWire
Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - StockTitan
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch - BioSpace
Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in... - Markets Insider
JAGXJaguar Health, Inc. Latest Stock News & Market Updates - StockTitan
Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference - Weatherford Democrat
Jaguar Health hires industry veteran as sales director - Investing.com
Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care - AccessWire
Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference - Weatherford Democrat
Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - Markets Insider
New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones - StockTitan
Companion Animal Health Market Report 2022: Featuring Zoetis, Jaguar Health, Elanco, Bayer, Merck & More - Yahoo Finance UK
Jaguar Health secures new patent for crofelemer in Jordan By Investing.com - Investing.com Australia
Jaguar Health secures new patent for crofelemer in Jordan - Investing.com
Jaguar Health Inc Stock (JAGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):